Please login to the form below
PsA
This page shows the latest PsA news and features for those working in and with pharma, biotech and healthcare.
Janssen’s Tremfya receives positive results for active psoriatic arthritis
clearance, alongside results that demonstrated positive joint efficacy, compared to existing PsA therapies. ... Through using the NMA approach to trial data, companies like Janssen are able to provide comparative evidence of PsA therapies.
Latest news
-
FDA approves Myovant’s oral pill Orgovyx for prostate cancer
Secondary endpoints from the study showed that relugolix was better than Lupron at suppressing testosterone quickly (four to 15 days after dosing started), suppressing prostate-specific antigen PSA at day 15
-
AZ/Merck's Lynparza improves survival in certain prostate cancers
CRPC, and a 52% prostate-specific antigen (PSA) response.
-
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
a 52% prostate-specific antigen (PSA) response.
-
J&J splashes $750m on anti-inflammatory drug bermekimab
J&J is already a leader in the immunology market, and recently filed its next-generation IL-23 inhibitor Tremfya in psoriatic arthritis (PsA) with the European Medicines Agency. ... loss. If it can win approval, Tremfya will become the first selective
-
Merck’s Keytruda significantly extends life in some prostate cancer patients
some evidence of tumour response with a decrease in prostate-specific antigen (PSA) levels. ... Another group of patients whose PSA levels were lower but whose cancer had spread to the bone lived for an average of 14.1 months on Keytruda.
More from news
Approximately 5 fully matching, plus 37 partially matching documents found.
Latest Intelligence
-
Pharma deals in March 2015
This is what BMS has secured with Bavarian Nordic's cancer vaccine targeting PSA in phase III for treatment of metastatic castration-resistant prostate cancer.
-
Pharma deals during June 2014
The phase II results showed a decline in PSA levels of more than 50% in the study of 124 patients.
-
The oncology market in Canada
The first peak was clearly the result of the introduction of PSA tests in the late 1980s; the cause of the second, smaller peak was not as definite, but researchers have ... attributed it to the publicity surrounding then-federal health minister Alan Rock
-
Knowledge is power
Future risk of prostate cancer is closely related to a man’s prostate-specific antigen (PSA) score; men screened at the age of 40 establish a baseline that can be tracked ... PSAs have always been a critical, controversial issue, which is why the
-
Special delivery
H&K secured Sherri Shepherd of ABC’s Emmy-winning morning talk show The View to donate her time to record radio PSAs. ... To-date, the PSA has reached more than 32 million. • A partnership with MTV garnered coverage on 16 and Pregnant and Teen Mom.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Fake News is Bad for your Health
How do you convey the risk of false positives when screening for breast cancer, or the fact that measuring PSA has no impact on surviving prostate cancer?
-
Barber shops provide a short cut to BP reduction
A few years ago, a London garage owner who owed his life to a timely PSA test, started offering free car MOT tests to men who agreed to get their prostate
-
Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis
Almost a third of people with psoriasis will develop PsA but patients may experience arthritic symptomsbefore any skin manifestations. ... unclear on what signs to check for a full and complete diagnosis of PsA?
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
